CytImmune Sciences, Inc.

With a core focus in oncology, CytImmune will leverage its proprietary pegylated colloidal gold tumor-targeting nanotechnology to develop a new pipeline of multifunctional, next generation therapeutics with faster development timelines, more efficient regulatory approvals, new commercialization value, and greater patient benefit from a wide array of available anti-cancer agents.

Website

9640 Medical Center Drive
Rockville, MD 20850 USA
(240)-864-2796